Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases.

Published

Journal Article

Inhibitors of mechanistic target of rapamycin are used in solid organ transplant procedures to avoid calcineurin inhibitor complications, including nephrotoxicity and malignancy. We present 2 cases of multivisceral transplantation for neuroendocrine tumor (NET) for which everolimus was implemented for its potential to prevent NET recurrence as well as preserve renal function. The first case was complicated by NET recurrence in the liver before initiation of everolimus. After initiation of everolimus, the patient developed a ventral hernia and elevated aminotransferase levels with nonspecific biopsy findings. The second case was complicated by cytomegalovirus infection with elevated everolimus trough levels as well as acute cellular rejection. Everolimus was reinitiated in both cases in addition to decreasing the dosage of tacrolimus, and there were no further complications. Everolimus was beneficial in stabilizing renal function in both patients and has the theoretical potential to prevent recurrence of NET.

Full Text

Duke Authors

Cited Authors

  • Rao, B; Segovia, MC; Kazimi, M; Parekh, R; Raoufi, M; Jafri, S-M

Published Date

  • March 2016

Published In

Volume / Issue

  • 48 / 2

Start / End Page

  • 485 - 488

PubMed ID

  • 27109983

Pubmed Central ID

  • 27109983

Electronic International Standard Serial Number (EISSN)

  • 1873-2623

Digital Object Identifier (DOI)

  • 10.1016/j.transproceed.2015.11.034

Language

  • eng

Conference Location

  • United States